Epitopea

Epitopea is developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumour-specific antigens, known as Cryptigen™ TSAs, that are broadly shared across multiple patients with the same tumour type.

CEO Alan C. Rigby. Courtesy – Epitopea.

Epitopea closed a $31m pre-Series A financing in October 2024 which saw new investors Investissement Québec, adMare BioInnovations and Jonathan Milner join existing backers Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, the Harrington Discovery Institute, IRICoR and Novateur Ventures in the round.

Career opportunities at Epitopea

Newsdesk

news@businessweekly.co.uk